Omid Rabbani, M.D.
M.D. Program, 1999-2003
Finch University of Health Sciences/The Chicago Medical School, North Chicago, IL
Interdisciplinary Studies Major in Neurobiological Sciences, 1994-1998
B.S., May 1998, Highest Honors
The University of Florida, Gainesville, FL
Thesis: The Neuroprotective Effects of Estrogen on Medial Septal Cholinergic Neurons
Following Fimbria-Fornix Lesion in the Female Sprague-Dawley Rat
Neurology Residency, 2004-2007
University of Florida/Shands Hospital, Gainesville, FL
Program Director: Hubert Fernandez, M.D.
Research Mentor: Stephen Nadeau, M.D.
Internship in Internal Medicine, 2003-2004
University of Florida/Shands Hospital, Gainesville, FL
Program Director: N. Lawrence Edwards, M.D.
Board Certified: American Board of Psychiatry and Neurology Certificate # 55364 (April 2009)
State of California
- Teaching Assistant for Medical Students in first year Medical Neuroscience Course, University of Florida, 1/04 Course Director: Louis Ritz, Ph.D.
- MDA Clinic Volunteer, Shands Medical Plaza, 2004-6
- Student Experiences and Rotations in Community Health (SEARCH) program sponsored by the Illinois Area Health Education Center, participant in program that offers students training opportunities at community/migrant health centers located in urban/rural areas of Illinois, 8/01
- Local Spiritual Assembly of the Baha’is of North Chicago, member, 2000-2001
- Local Spiritual Assembly of the Baha’is of Collier County, Naples, FL, member, 2009- 2011
- Chicago Medical School Health Care Project, volunteer in free clinic for the homeless, 3/01
American Academy of Neurology, member, 2004-present
- Hedna, V.S.; Jain, S.; Rabbani, O. and S.E. Nadeau. (2011) Mechanisms of arm paresis in middle cerebral artery distribution stroke. (pending)
- Rabbani, O.; Bowen, L.E.; Watson, R.T.; Valenstein, E. and M.S. Okun. (2004) Alien limb syndrome and moya-moya disease. Movement Disorders, 19(11):1317-20.
- Shi, J.; Panickar, K.S.; Yang, S.H.; Rabbani, O.; Day, A.L. and J.W. Simpkins. (1998) Estrogen attenuates over-expression of beta-amyloid precursor protein messenger RNA in an animal model of focal ischemia. Brain Research, 810(1-2): 87-92.
- Simpkins, J.W.; Rabbani, O.; Shi, J.; Panickar, K.S.; Green, P.S. and A.L. Day. (1998) A system for the brain-enhanced delivery of estradiol: an assessment of its potential for the treatment of Alzheimer’s disease and stroke. Die Pharmazie, 53(8): 505-11.
- Rabbani, O.; Panickar, K.S.; Rajakumar, G.; King, M.A.; Bodor, N.; Meyer, E.M. and J.W. Simpkins. (1997) 17 beta-estradiol attenuates fimbrial lesion-induced decline of ChAT-immunoreactive neurons in the rat medial septum. Experimental Neurology, 146(1): 179-86.
- A Randomized Double Blind, Placebo Controlled of XXX in Subjects Beginning Treatment within Six Hours of the Onset of Acute Ischemic Stroke.
- A Phase II, Randomized, Open Label, Safety and Tolerability Trial Comparing XXX with Routine Care in Patients with Chronic Painful Diabetic Peripheral Neuropathy.
- A Randomized Controlled, Open Label, Parallel, Group Study to evaluate the Effect of Regularly Scheduled Neutralized Antibody Testing on Treatment Patterns VS. usual Care in High Dose Interferon Treated Subjects.
- A Double Blind, Randomized, Placebo Controlled, Parallel Group Multicenter Phase IIb/III Study to Assess the Efficacy and Safety of XXX in Acute Ischemic Stroke.
- A Double Blind, Placebo Controlled, Randomized Parallel Group Safety, Efficacy and Dose Response Trial of Two Different Dose Levels of XXX in Patients with Signs and Symptoms of Acute Ischemic Stroke,.
- A Randomized, Multicenter, Placebo-Controlled and Active Reference (XXX) Comparison Study to Evaluate the Efficacy and Safety of YYY in Subjects with Relapsing-Remitting Multiple Sclerosis.
- A Randomized, Double Blind, Double Dummy Placebo Controlled, Crossover Study to Evaluate the efficacy of XXX versus YYY for the acute treatment of migraine when administered during the moderate to severe pain phase of the migraine.
- A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of XXX in the Treatment of Psychosis in Parkinson’s Disease
- Multicenter, Double-blind, Randomized, Paralled-group, Monotherapy, Active-Control Study to Determine the Efficacy and Safety of XXX versus YYY in Patients with Relapsing-Remitting Multiple Sclerosis.
- JCV Antibody Program in Patints with Relapsing Multiple Sclerosis Receiving or Considering Treatment with XXX.
- A Multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of XXX injection 40 mg administered three times a week compared to placebo in a double-blind design.
- A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of XXX as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson’s Disease.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of XXX in Patients With Mild to Moderate Alzheimer’s Disease.
- A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XXX and YYY in Parkinson’s Disease Subjects with Motor Fluctuations
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study To Evaluate The Efficacy And Safety Of XXX In Patients With Mild To Moderate Alzheimer’s Disease
- A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXX in Subjects with Moderate to Severe Parkinson’s Disease
Undergraduate Student Grant, American Foundation for Aging Research, 1997.
Shands Hospital Star Certificate for Dedication to Patient Care, 2004